ClinicalTrials.gg
CompletedNCT00340704Updated Feb 17, 2016Results posted

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

A Phase 2 interventional study of tamsulosin hydrochloride in Bladder, Neurogenic, sponsored by Boehringer Ingelheim. Completed at 72 sites in 14 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 81 studies in Urinary Bladder, Neurogenic with a site in United States — 21 open to participants now, 29 under way, 1 of them phase 3. Urinary Bladder, Neurogenic · United States.

Enrollment
8th of 64
143 · median 30
Started
2006
with 2 others
Phase 2
10 of 81
1 open now
Registered
1st of 81
by date
Lead sponsor
2 of 81
Boehringer Ingelheim

Among the 81 studies in Urinary Bladder, Neurogenic with a site in United States, this one is the 8th largest by enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2006, is one of 10 in phase 2, and was the 1st registered.

Urinary Bladder, Neurogenic

191 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.

Browse Urinary Bladder, Neurogenic studies →

Open to participants now

21 of the 81 studies in Urinary Bladder, Neurogenic with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Urinary Bladder, Neurogenic studies recruiting now, 11 (44%) set no upper age limit and 9 (36%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Urinary Bladder, Neurogenic with a site in United States, or all of them as a file.
02

Study summary

Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.

03

Conditions studied

  • Bladder, Neurogenic

Keywords

  • tamsulosin
  • pediatric
  • neurogenic bladder
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neuropathic bladder secondary to known neurological disorder
  • Elevated detrusor leak point pressures (LPP) ≥40 cm H2O confirmed by two measurements at baseline

Exclusion criteria

Exclusion Criteria:

  • abnormalities as determined by the investigator
  • A history of relevant orthostatic hypotension, fainting spells or blackouts
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    1. Low dose group

    Drug: tamsulosin hydrochloride

  • Experimental
    2. Medium dose group

    Drug: tamsulosin hydrochloride

  • Experimental
    3. High dose group

    Drug: tamsulosin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover

    Group D-Denovo: Leak point pressure (LPP) Response at(response defined as a subject who achieves an LPP pressure \<40 cm H2O) at the end of treatment based on two confirmatory values. Group D-527.51 Rollover: Leak point pressure (LPP) Response at (response defined as a subject who achieves an LPP pressure \<40 cm H2O) last value of the treatment based on two confirmatory values. The last value on treatment included any final value prior to discontinuation of treatment, regardless of the length of treatment. Detrusor leak point pressure (LPP) recorded in cm H2O which was obtained using a standard urodynamic technique, a cystometrogram. Descriptive statistics were used to assess this endpoint. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.

    Time frame: Group D-Denovo: Week 52. Group D-527.51 Rollover: Week 1, Week 2, Week 3 and Week 4 prior to dose administration and Week9 (optional), Week 13 (additional), Week 26 (optional) and Week 52 after drug administration.

  2. Number of LPP Responders at Each Visit Over Time (Classified by Last Value on Treatment) for Group D-527.51 Rollover.

    Number of Leak point pressure (LPP) Responders at each visit (week) over time (classified by last value on treatment). Due to the early termination of the study, most of the LPP assessments were conducted within Weeks 1-9 of treatment. Summary of LPP response rates provided over time.The subjects are classified according to the treatment they were receiving at the last value on treatment. Therefore, no assumptions can be made regarding what dose they were receiving at a particular time point. LD: Low Dose, MD: Medium Dose and HD: High Dose This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

    Time frame: Week 1 (Visit 3) , Week 2 (Visit 4) , Week 3 (Visit 5) and Week 4 (Visit 6) prior to dose administration and Week 9 (Visit 7) (optional), Week 13 (Visit 8) (additional), Week 26 (Visit 9) (optional) and Week 52 (Visit 11) after drug administration.

Secondary outcomes

  1. Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover

    Early responders who maintained their detrusor leak point pressure (LPP) below 40 cm H2O during the study. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2,3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, However this endpoint was not analysed for Group D-527.51 Rollover as very limited data were collected due to early termination of the study \& no alternative endpoint was defined in the Group D-527.51 rollover, so only the results for Group D-Denovo is provided.

    Time frame: Week 1 to Week 52 (Time frame for all weeks are described study wise in the Description).

  2. Change From Baseline in LPP for Group D-527.51 Rollover

    Median change from baseline in detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

    Time frame: Baseline and week 1

  3. Percent Change From Baseline in LPP for Group D-527.51 Rollover

    Percent change from baseline in actual detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and Week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

    Time frame: Baseline and Week 1

  4. Response Defined as Stabilization or Improvement of Hydroureter Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover

    Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydroureter in the Group D-527.51 Rollover. Hydroureter response is defined as improvement or stabilization based upon the presence or absence of hydroureter at end of treatment compared to baseline. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.

    Time frame: Group D-Denovo: Baseline and Week 52. Group D-527.51 Rollover: Baseline, Week 26 and Week 52.

  5. Response Defined as Stabilization or Improvement of Hydronephrosis Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover

    Response defined as stabilization or improvement of hydronephrosis measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydronephrosis in the Group D-527.51 Rollover. Hydronephrosis response is defined as an improvement or stabilization based upon ultrasound grading at the end of the study. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization.

    Time frame: Group D-Denovo: Baseline and Week 52. Group D-527.51 Rollover: Baseline, Week 26 and Week 52.

  6. LPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover

    Response rates of LPP responders (2 LPP values \< 40 cm H2O) at any time during the trial by treatment group. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2, 3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.

    Time frame: Week 1 to Week 52 (described study wise in the Description).

  7. Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover

    Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Below mentioned result are the number of subjects who had the clinical relevant abnormalities for the preferred term 'Hepatic enzyme increased'. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

    Time frame: From first drug administration until 28 days after last study drug administration, upto 395 days

  8. Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse Events and Cognitive Testing for Group D-Denovo

    Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Subjects who experienced orthostatic hypotension during orthostatic testing were reported as adverse events. This Outcome Measure was only pre-specified for Group D-Denovo, so results of this group is provided.

    Time frame: From first drug administration until 28 days after last study drug administration, upto 450 days

  9. Vision Testing for Group D-Denovo

    Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-Denovo subjects, so results of this group is provided.

    Time frame: Baseline, Week 26 and Week 52.

  10. Vision Testing for Group D-527.51 Rollover

    Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

    Time frame: Baseline and Week 52

  11. Cmax,1

    Maximum measured concentration of the analyte in plasma following the first dose, Cmax,1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.

  12. Tmax, 1

    Time from dosing to maximum measured concentration of the analyte in plasma after administration of the first dose, tmax, 1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.

  13. Cmax, 1 ,DW ,Norm

    Dose- and weight-normalized Cmax,1 (Cmax,1,DW,norm). Weight normalization of Cmax,1 was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.

  14. Cpre,ss

    Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose, Cpre,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  15. Cmax,ss

    Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  16. Cmax,ss, DW, Norm

    Dose- and weight-normalized for Cmax,ss, Cmax,ss, DW, norm. Weight normalization of Cmax,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  17. Cmin,ss

    Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmin,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  18. Tmax,ss

    Time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ, tmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  19. AUCτ,ss

    Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ , AUCτ,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  20. AUCτ ,ss ,DW ,Norm

    Dose- and weight-normalized of AUCτ ,ss ( AUCτ ,ss ,DW ,norm). Weight normalization of AUCτ,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  21. λz,ss

    Terminal rate constant of the analyte in plasma at steady state, λz,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  22. t1/2,ss

    Terminal half-life of the analyte in plasma at steady state, t1/2,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  23. MRTpo,ss

    Mean residence time of the analyte in the body at steady state after oral administration,MRTpo,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  24. CL/F,ss,W,Norm

    Weight-normalized CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration), CL/F,ss,W,norm. Weight-normalized CL/F,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  25. Vz/F,ss,W,Norm

    Weight-normalized Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration), Vz/F,ss,W,norm. Weight-normalized VzF,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

  26. RA,Cmax

    The accumulation ratio was calculated from the patients who were randomised to the low dose group and for whom both parameters at first dose and steady state dose were available. Accumulation ratios of tamsulosin HCl in plasma at steady state after multiple dose administration over a uniform dosing interval τ, expressed as ratio of Cmax at steady state and after single dose. The accumulation ratio RA,Cmax was calculated as: Cmax,ss/Cmax,1. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results from this group is provided.

    Time frame: -0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.

07

Results

Posted Feb 17, 2016
Limitations and caveats
In Group D-527.51 Rollover study, due to the early termination caution should be used in interpreting these results due to the impact of the early termination, as well as the impact of the study design on interpretation of results by dose.

Participant flow

This trial has 3 different Data base locks (DBLs) based on 3 separate populations PK/PD, Group D-Denovo \& Group D-527.51 Rollover. For population PK/PD the DBL date was 18July2007, Group D-Denovo the DBL date was 23Jan2009 \& Group D-527.51 Rollover the DBL date was 11Sep2009.

PK Study
Participant flow — PK Study
MilestoneTamsulosin - Low Dose Level (PK Study)Tamsulosin - Medium Dose Level (PK Study)Tamsulosin - High Dose Level (PK Study)Tamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Started101011000000
Completed10910000000
Not completed011000000
Withdrew: Adverse event010000000
Withdrew: Not treated001000000
Group D- Denovo & 527.51 Rollover Study
Participant flow — Group D- Denovo & 527.51 Rollover Study
MilestoneTamsulosin - Low Dose Level (PK Study)Tamsulosin - Medium Dose Level (PK Study)Tamsulosin - High Dose Level (PK Study)Tamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Started000292137541329
Pk study subjects entered group d-denovo0007518000
Completed000271630110
Not completed000257531229
Withdrew: Adverse event000240011
Withdrew: Protocol violation000001000
Withdrew: Withdrawal by subject000013000
Withdrew: Other reason not defined above000003531128

Outcome measures

PrimaryPercentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover

Group D-Denovo: Leak point pressure (LPP) Response at(response defined as a subject who achieves an LPP pressure \<40 cm H2O) at the end of treatment based on two confirmatory values. Group D-527.51 Rollover: Leak point pressure (LPP) Response at (response defined as a subject who achieves an LPP pressure \<40 cm H2O) last value of the treatment based on two confirmatory values. The last value on treatment included any final value prior to discontinuation of treatment, regardless of the length of treatment. Detrusor leak point pressure (LPP) recorded in cm H2O which was obtained using a standard urodynamic technique, a cystometrogram. Descriptive statistics were used to assess this endpoint. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.

Time frame:
Group D-Denovo: Week 52. Group D-527.51 Rollover: Week 1, Week 2, Week 3 and Week 4 prior to dose administration and Week9 (optional), Week 13 (additional), Week 26 (optional) and Week 52 after drug administration.
Reported as:
Number · percentage of responders
Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover
percentage of respondersTamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover73.135.726.767.958.320.7
PrimaryNumber of LPP Responders at Each Visit Over Time (Classified by Last Value on Treatment) for Group D-527.51 Rollover.

Number of Leak point pressure (LPP) Responders at each visit (week) over time (classified by last value on treatment). Due to the early termination of the study, most of the LPP assessments were conducted within Weeks 1-9 of treatment. Summary of LPP response rates provided over time.The subjects are classified according to the treatment they were receiving at the last value on treatment. Therefore, no assumptions can be made regarding what dose they were receiving at a particular time point. LD: Low Dose, MD: Medium Dose and HD: High Dose This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

Time frame:
Week 1 (Visit 3) , Week 2 (Visit 4) , Week 3 (Visit 5) and Week 4 (Visit 6) prior to dose administration and Week 9 (Visit 7) (optional), Week 13 (Visit 8) (additional), Week 26 (Visit 9) (optional) and Week 52 (Visit 11) after drug administration.
Reported as:
Number · Participants
Number of LPP Responders at Each Visit Over Time (Classified by Last Value on Treatment) for Group D-527.51 Rollover.
ParticipantsTamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Week 1 (N= 40 (LD), 12 (MD), 27 (HD))3810
Week 2 (N= 2 (LD), 7 (MD), 27 (HD))272
Week 3 (N= 3 (LD), 0 (MD), 22 (HD))205
Week 4 (N= 1 (LD), 0 (MD), 3 (HD))100
Week 9 (N= 7 (LD), 2 (MD), 16 (HD))525
Week 13 (N= 4 (LD), 0 (MD), 2 (HD))101
Week 26 (N= 2 (LD), 0 (MD), 3 (HD))101
Week 52 (N= 1 (LD), 1 (MD), 0 (HD))110
SecondaryEarly Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover

Early responders who maintained their detrusor leak point pressure (LPP) below 40 cm H2O during the study. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2,3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, However this endpoint was not analysed for Group D-527.51 Rollover as very limited data were collected due to early termination of the study \& no alternative endpoint was defined in the Group D-527.51 rollover, so only the results for Group D-Denovo is provided.

Time frame:
Week 1 to Week 52 (Time frame for all weeks are described study wise in the Description).
Reported as:
Number · Participants
Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover
ParticipantsTamsulosin-low Dose Level (Group D-Denovo)Tamsulosin-medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover1753———
SecondaryChange From Baseline in LPP for Group D-527.51 Rollover

Median change from baseline in detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

Time frame:
Baseline and week 1
Reported as:
Median · cm H2O
Change From Baseline in LPP for Group D-527.51 Rollover
cm H2OTamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Baseline (N= 53 (LD), 12 (MD), 29(HD))48.50 ± 14.4748.5 ± 11.1955.50 ± 24.52
Week 1 - Actual (N= 39 (LD), 9 (MD),22 (HD))29.00 ± 8.5049.50 ± 8.3064.75 ± 27.20
Week 1 - Change (N= 39 (LD), 9 (MD),22 (HD))-25.5 ± 15.18-2 ± 13.68-1.25 ± 24.97
SecondaryPercent Change From Baseline in LPP for Group D-527.51 Rollover

Percent change from baseline in actual detrusor leak point pressure (LPP) by treatment group (subjects are classified according to the treatment they were taking at end of treatment) and Week. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The results from Week 1 were reported because there were very few subjects who reported data at subsequent visits due to the termination of the trial. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

Time frame:
Baseline and Week 1
Reported as:
Median · percent change
Percent Change From Baseline in LPP for Group D-527.51 Rollover
percent changeTamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Baseline (N= 53 (LD), 12 (MD), 29 (HD))48.50 ± 14.4748.50 ± 11.1955.50 ± 24.52
Week 1 - Actual (N= 39 (LD), 9 (MD), 22 (HD))29.00 ± 8.5049.50 ± 8.3064.75 ± 27.20
Week 1 - Change (N= 39 (LD), 9 (MD), 22 (HD))-48.48 ± 18.65-3.88 ± 22.43-2.71 ± 40.41
SecondaryResponse Defined as Stabilization or Improvement of Hydroureter Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover

Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydroureter in the Group D-527.51 Rollover. Hydroureter response is defined as improvement or stabilization based upon the presence or absence of hydroureter at end of treatment compared to baseline. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.

Time frame:
Group D-Denovo: Baseline and Week 52. Group D-527.51 Rollover: Baseline, Week 26 and Week 52.
Reported as:
Number · Participants
Response Defined as Stabilization or Improvement of Hydroureter Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover
ParticipantsTamsulosin-low Dose Level (Group D-Denovo)Tamsulosin-medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Right Kidney26152843819
Left Kidney24142943817
SecondaryResponse Defined as Stabilization or Improvement of Hydronephrosis Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover

Response defined as stabilization or improvement of hydronephrosis measured by renal ultrasound compared to baseline by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment) at week 52 for Group D-Denovo and (subjects are classified according to the treatment they were taking at the end of treatment) at last value on treatment for Group D-527.51 Rollover. Baseline assessments were obtained from trial 527.51 for Group D-527.51 Rollover. The overall treatment duration was not sufficient to reach any meaningful conclusions regarding improvement or stabilization of hydronephrosis in the Group D-527.51 Rollover. Hydronephrosis response is defined as an improvement or stabilization based upon ultrasound grading at the end of the study. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization.

Time frame:
Group D-Denovo: Baseline and Week 52. Group D-527.51 Rollover: Baseline, Week 26 and Week 52.
Reported as:
Number · Participants
Response Defined as Stabilization or Improvement of Hydronephrosis Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover
ParticipantsTamsulosin-low Dose Level (Group D-Denovo)Tamsulosin-medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Right Kidney26152839817
Left Kidney24142642717
SecondaryLPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover

Response rates of LPP responders (2 LPP values \< 40 cm H2O) at any time during the trial by treatment group. Timeframe for Group D-Denovo: Low dose: Week 1, 3 \& 4 prior to dose and Week 2, 9 \& 26 (optional), 13(additional) \& 52 post dose. Medium dose: Week 1, 2 \& 4 prior to dose and Week 3, 9(optional), 13(additional), 26 (optional) \& 52 post dose. High dose: Week 1, 2 \& 3 prior to dose administration and Week 4, 9(optional), 13(additional), 26 (optional) \& 52 post dose. Group D-527.51 Rollover: Week 1, 2, 3 \& 4 prior to dose and Week 9 \&26 (optional),13 (additional) \& 52 post dose. This Outcome Measure was only pre-specified for Group D-Denovo and Group D-527.51 Rollover subjects, so results of these two groups are provided.

Time frame:
Week 1 to Week 52 (described study wise in the Description).
Reported as:
Number · participants
LPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover
participantsTamsulosin-low Dose Level (Group D-Denovo)Tamsulosin-medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
LPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover26161642812
SecondaryNumber of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover

Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Below mentioned result are the number of subjects who had the clinical relevant abnormalities for the preferred term 'Hepatic enzyme increased'. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

Time frame:
From first drug administration until 28 days after last study drug administration, upto 395 days
Reported as:
Number · Participants
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover
ParticipantsTamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover100
SecondaryNumber of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse Events and Cognitive Testing for Group D-Denovo

Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse events and Cognitive Testing. Relevant findings or worsening of baseline conditions were reported as adverse events. Subjects who experienced orthostatic hypotension during orthostatic testing were reported as adverse events. This Outcome Measure was only pre-specified for Group D-Denovo, so results of this group is provided.

Time frame:
From first drug administration until 28 days after last study drug administration, upto 450 days
Reported as:
Number · Participants
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse Events and Cognitive Testing for Group D-Denovo
ParticipantsTamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)
Blood urine present001
Body temperature increased001
Orthostatic hypotension130
SecondaryVision Testing for Group D-Denovo

Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at Week 52 or end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-Denovo subjects, so results of this group is provided.

Time frame:
Baseline, Week 26 and Week 52.
Reported as:
Number · Participants
Vision Testing for Group D-Denovo
ParticipantsTamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)
Right Eye (Week 26) - No Change11712
Right Eye (Week 26) - Decrease in visual acuity818
Right Eye (Week 26) - Increase in visual acuity8411
Right Eye (Week 26) - Missing296
Left Eye (Week 26) - No Change11619
Left Eye (Week 26) - Decrease in visual acuity714
Left Eye (Week 26) - Increase in visual acuity958
Left Eye (Week 26) - Missing296
Right Eye (Week 52) - No Change7616
Right Eye (Week 52) - Decrease in visual acuity1024
Right Eye (Week 52) - Increase in visual acuity11612
Right Eye (Week 52) - Missing175
Left Eye (Week 52) - No Change11512
Left Eye (Week 52) - Decrease in visual acuity636
Left Eye (Week 52) - Increase in visual acuity11714
Left Eye (Week 52) - Missing165
SecondaryVision Testing for Group D-527.51 Rollover

Number of subjects with a change from baseline in visual acuity by treatment group (subjects are classified according to the treatment they were taking at end of treatment). They were analysed based on the below mentioned category in both the Eyes: 1) No Change 2) Decrease in visual acuity 3) Increase in visual acuity 4) Missing. Missing includes subjects with no baseline exam and subjects with exam scores missing. This Outcome Measure was only pre-specified for Group D-527.51 Rollover subjects, so results of this group is provided.

Time frame:
Baseline and Week 52
Reported as:
Number · Participants
Vision Testing for Group D-527.51 Rollover
ParticipantsTamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Right Eye - No Change321012
Right Eye - Decrease in visual acuity524
Right Eye - Increase in visual acuity1216
Right Eye - Missing507
Left Eye - No Change311212
Left Eye - Decrease in visual acuity813
Left Eye - Increase in visual acuity1007
Left Eye - Missing507
SecondaryCmax,1

Maximum measured concentration of the analyte in plasma following the first dose, Cmax,1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.
Reported as:
Geometric mean · ng/mL
Cmax,1
ng/mLPK Study - Single Dose
Cmax,11.67 ± 68.80
SecondaryTmax, 1

Time from dosing to maximum measured concentration of the analyte in plasma after administration of the first dose, tmax, 1. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.
Reported as:
Median · hours
Tmax, 1
hoursPK Study - Single Dose
Tmax, 16 (2 to 8)
SecondaryCmax, 1 ,DW ,Norm

Dose- and weight-normalized Cmax,1 (Cmax,1,DW,norm). Weight normalization of Cmax,1 was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- single dose group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h and 8h after the drug administration.
Reported as:
Geometric mean · ng/mL/mg*kg
Cmax, 1 ,DW ,Norm
ng/mL/mg*kgPK Study - Single Dose
Cmax, 1 ,DW ,Norm1120 ± 67.20
SecondaryCpre,ss

Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose, Cpre,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · ng/mL
Cpre,ss
ng/mLTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
Cpre,ss0.914 ± 1591.83 ± 1314.03 ± 70.60
SecondaryCmax,ss

Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · ng/mL
Cmax,ss
ng/mLTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
Cmax,ss2.79 ± 59.505.02 ± 94.8014.10 ± 50.30
Statistical analysis
  • Tamsulosin - Low Dose Level (Steady State - PK Study) vs Tamsulosin - Medium Dose Level (Steady State - PK Study) vs Tamsulosin - High Dose Level (Steady State - PK Study) · Slope: 1.0039 · 95% CI 0.6499 to 1.3579Based on the estimate for the slope parameter, a two sided 95% confidence interval for the slope was computed. Perfect dose proportionality would correspond to a slope of 1. Standard error (SE) of the mean is actually SE of the slope.
SecondaryCmax,ss, DW, Norm

Dose- and weight-normalized for Cmax,ss, Cmax,ss, DW, norm. Weight normalization of Cmax,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · ng/mL/mg*kg
Cmax,ss, DW, Norm
ng/mL/mg*kgTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
Cmax,ss, DW, Norm2040 ± 74.301850 ± 85.702240 ± 47.60
SecondaryCmin,ss

Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ, Cmin,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · ng/mL
Cmin,ss
ng/mLTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
Cmin,ss0.747 ± 99.701.52 ± 1304.01 ± 68.50
SecondaryTmax,ss

Time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ, tmax,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Median · hours
Tmax,ss
hoursTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
Tmax,ss5.00 ± 99.75.92 ± 1305.01 ± 68.5
SecondaryAUCτ,ss

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ , AUCτ,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · ng*h/mL
AUCτ,ss
ng*h/mLTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
AUCτ,ss35.80 ± 75.6068.20 ± 94.70175.00 ± 61.00
Statistical analysis
  • Tamsulosin - Low Dose Level (Steady State - PK Study) vs Tamsulosin - Medium Dose Level (Steady State - PK Study) vs Tamsulosin - High Dose Level (Steady State - PK Study) · Slope: 0.98 · 95% CI 0.5934 to 1.3666Based on the estimate for the slope parameter, a two sided 95% confidence interval for the slope was computed. Perfect dose proportionality would correspond to a slope of 1. Standard error of the mean is actually standard error of the slope.
SecondaryAUCτ ,ss ,DW ,Norm

Dose- and weight-normalized of AUCτ ,ss ( AUCτ ,ss ,DW ,norm). Weight normalization of AUCτ,ss was performed by dividing the respective quantities by the reciprocal of body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · ng*h/mL/mg*kg
AUCτ ,ss ,DW ,Norm
ng*h/mL/mg*kgTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
AUCτ ,ss ,DW ,Norm26100 ± 91.1025200 ± 82.9027700 ± 59.10
Secondaryλz,ss

Terminal rate constant of the analyte in plasma at steady state, λz,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · 1/hours
λz,ss
1/hoursTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
λz,ss0.0589 ± 48.100.0671 ± 40.800.0496 ± 31.90
Secondaryt1/2,ss

Terminal half-life of the analyte in plasma at steady state, t1/2,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · hours
t1/2,ss
hoursTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
t1/2,ss11.80 ± 48.1010.30 ± 40.8014.00 ± 31.90
SecondaryMRTpo,ss

Mean residence time of the analyte in the body at steady state after oral administration,MRTpo,ss. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · hours
MRTpo,ss
hoursTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
MRTpo,ss18.70 ± 50.5017.60 ± 35.0020.90 ± 23.60
SecondaryCL/F,ss,W,Norm

Weight-normalized CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration), CL/F,ss,W,norm. Weight-normalized CL/F,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · L/h/kg
CL/F,ss,W,Norm
L/h/kgTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
CL/F,ss,W,Norm0.0383 ± 91.100.0397 ± 82.900.0361 ± 59.10
SecondaryVz/F,ss,W,Norm

Weight-normalized Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration), Vz/F,ss,W,norm. Weight-normalized VzF,ss was calculated by dividing the respective quantities by body weight in kg. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results of this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · L/kg
Vz/F,ss,W,Norm
L/kgTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)
Vz/F,ss,W,Norm0.65 ± 83.800.591 ± 103.000.729 ± 96.00
SecondaryRA,Cmax

The accumulation ratio was calculated from the patients who were randomised to the low dose group and for whom both parameters at first dose and steady state dose were available. Accumulation ratios of tamsulosin HCl in plasma at steady state after multiple dose administration over a uniform dosing interval τ, expressed as ratio of Cmax at steady state and after single dose. The accumulation ratio RA,Cmax was calculated as: Cmax,ss/Cmax,1. This Outcome Measure was only pre-specified for PK Study- steady state group subjects, so results from this group is provided.

Time frame:
-0.25h prior to dose and 2h, 4h, 6h, 8h, 10h, 24h and 33h after the drug administration.
Reported as:
Geometric mean · Ratio
RA,Cmax
RatioTamsulosin - Low Dose Level (Steady State - PK Study)
RA,Cmax1.58 ± 65.20

Adverse events

Collected over From first drug administration until 28 days after last study drug administration, upto 80 days (Steady State - PK study), upto 450 days (Group D-Denovo) and upto 395 days (Group D-527.51 Rollover).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tamsulosin - Low Dose Level (Steady State - PK Study)—0/10 (0%)5/10 (50%)
Tamsulosin - Medium Dose Level (Steady State - PK Study)—1/10 (10%)5/10 (50%)
Tamsulosin - High Dose Level (Steady State - PK Study)—0/10 (0%)3/10 (30%)
Tamsulosin - Low Dose Level (Group D-Denovo)—2/82 (2.4%)51/82 (62.2%)
Tamsulosin - Medium Dose Level (Group D-Denovo)—3/61 (4.9%)25/61 (41%)
Tamsulosin - High Dose Level (Group D-Denovo)—4/41 (9.8%)33/41 (80.5%)
Tamsulosin - Low Dose Level (Group D-527.51 Rollover)—1/93 (1.1%)31/93 (33.3%)
Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)—1/41 (2.4%)10/41 (24.4%)
Tamsulosin - High Dose Level (Group D-527.51 Rollover)—1/29 (3.4%)9/29 (31%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)Tamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Ventriculoperitoneal shunt malfunctionInjury, poisoning and procedural complications0/101/100/101/821/610/410/930/410/29
Urinary tract infectionInfections and infestations0/100/100/100/820/612/410/931/411/29
Tibial torsionCongenital, familial and genetic disorders0/100/100/100/820/611/410/930/410/29
CellulitisInfections and infestations0/100/100/100/820/611/410/930/410/29
GastroenteritisInfections and infestations0/100/100/100/820/610/410/931/410/29
HydrocephalusNervous system disorders0/100/100/102/821/610/410/930/410/29
Tethered cord syndromeNervous system disorders0/100/100/100/820/611/410/930/410/29
Dengue feverInfections and infestations0/100/100/100/821/610/410/930/410/29
AsthmaRespiratory, thoracic and mediastinal disorders0/100/100/100/821/610/410/930/410/29
Peritoneal cystGastrointestinal disorders0/100/100/101/820/610/410/930/410/29
Most frequent other events
Showing 10 of 24
Most frequent other events
EventTamsulosin - Low Dose Level (Steady State - PK Study)Tamsulosin - Medium Dose Level (Steady State - PK Study)Tamsulosin - High Dose Level (Steady State - PK Study)Tamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)
Urinary tract infectionInfections and infestations2/101/101/1015/8211/6116/419/933/414/29
PyrexiaGeneral disorders2/100/100/1012/823/616/411/931/411/29
RashSkin and subcutaneous tissue disorders0/102/100/101/822/610/410/931/410/29
PharyngitisInfections and infestations0/100/100/1011/821/612/412/931/411/29
VomitingGastrointestinal disorders1/101/101/109/824/613/413/932/410/29
Abdominal painGastrointestinal disorders0/100/101/104/820/611/412/930/411/29
Abdominal pain upperGastrointestinal disorders1/100/100/103/821/611/412/930/410/29
DiarrhoeaGastrointestinal disorders0/100/101/104/822/612/411/932/410/29
Catheter related complicationGeneral disorders1/100/100/100/820/610/410/930/410/29
MassGeneral disorders1/100/100/101/820/610/410/930/410/29

Baseline characteristics

Treated Set: Includes all patients who are dispensed study medication and are documented to have taken at least one dose of treatment. In this study, some of the subjects are in multiple phases: PK and Group D-Denovo. Thus, the baseline characteristics are based on the unique subject entered into the study.

Age, Continuous
Age, Continuous(years)Tamsulosin - Low Dose Level (PK Study)Tamsulosin - Medium Dose Level (PK Study)Tamsulosin - High Dose Level (PK Study)Tamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)Total
Mean8.7 ± 4.56.5 ± 2.68.8 ± 3.76.8 ± 3.46.3 ± 3.78.1 ± 3.88.1 ± 3.87.0 ± 3.48.3 ± 4.17.7 ± 3.7
Sex: Female, Male
Sex: Female, Male(Participants)Tamsulosin - Low Dose Level (PK Study)Tamsulosin - Medium Dose Level (PK Study)Tamsulosin - High Dose Level (PK Study)Tamsulosin - Low Dose Level (Group D-Denovo)Tamsulosin - Medium Dose Level (Group D-Denovo)Tamsulosin - High Dose Level (Group D-Denovo)Tamsulosin - Low Dose Level (Group D-527.51 Rollover)Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)Tamsulosin - High Dose Level (Group D-527.51 Rollover)Total
Female535127102181283
Male575109933517100
08

Study locations

72 sites
  • Birmingham, Alabama 35233, United States
  • Los Angeles, California 90027, United States
  • Jacksonville, Florida 32207, United States
  • Tampa, Florida 33614, United States
  • Springfield, Illinois 62702, United States
  • Indianapolis, Indiana 46202, United States
  • Shreveport, Louisiana 71106, United States
  • St Louis, Missouri 63110, United States
  • Buffalo, New York 14222, United States
  • Lake Success, New York 11042, United States
  • Tarrytown, New York 10591, United States
  • Winston Salem, North Carolina 27157, United States
  • Akron, Ohio 44308, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Nashville, Tennessee 37232, United States
  • Dallas, Texas 75235, United States
  • Houston, Texas 77030, United States
  • Salt Lake City, Utah 84132, United States
  • Madison, Wisconsin 53792, United States
  • Gent, 9000, Belgium
  • Santo Andre, 09060-650, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Halifax, B3K 6R8, Canada
  • Montreal, H3H 1P3, Canada
  • Montreal, H3T 1J5, Canada
  • Toronto, M5G 1X8, Canada
  • Berlin, 10115, Germany
  • Deggendorf, 94469, Germany
  • Essen, 45122, Germany
  • Hamburg, 22763, Germany
  • Mainz, 55101, Germany
  • Ahmedabad, 380-006, India
  • Belgaum, 590-010, India
  • Bengaluru, 560-010, India
  • Hyderabaad, 500-029, India
  • Kochin, 682-026, India
  • Lucknow, 226-003, India
  • Lucknow, 226-014, India
  • Ludhiana, 141-001, India
  • Ludhiana, 141-008, India
  • Manipal, 576-104, India
  • Mumbai, 400-008, India
  • Nadiad, 387-001, India
  • Nagpur, India
  • New Delhi, 110-029, India
  • Pune, 411-001, India
  • Pune, 411-053, India
  • Cagliari, 09134, Italy
  • Firenze, 50139, Italy
  • Roma, 00165, Italy
  • Gwangju, 501-757, Korea, Republic of
  • In Cheon, 400-711, Korea, Republic of
  • Pusan, 602-739, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Leon, 37660, Mexico
  • Puebla, CP 72190, Mexico
  • Manila, 1000, Philippines
  • Pasig City, 1604, Philippines
  • Quezon City, 1104, Philippines
  • Moscow, 119991, Russian Federation
  • St. Petersburg, 194100, Russian Federation
  • Bloemfontein, 9300, South Africa
  • Cape Town, 7700, South Africa
  • Johannesburg, South Africa
  • Pretoria, 0028, South Africa
  • Roodepoort, South Africa
  • Barcelona, 08025, Spain
  • Madrid, 28046, Spain
  • Malaga, 29011, Spain
  • Chernivtsy, 58002, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2006
First posted
Jun 21, 2006
Start
Apr 2006
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Feb 17, 2016
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00340704
Responsible party
Sponsor
First posted
Jun 21, 2006
Start date
Apr 2006
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Feb 17, 2016
Last update
Feb 17, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion